Capital Fund Management (CFM)
RVNC

Capital Fund Management (CFM)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital Fund Management (CFM)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-45,100
Closed -$396K – 2334
2023
Q4 		$396K Buy
45,100
+3,200
+8% +$26.2K ﹤0.01% 2024
2023
Q3 		$481K Buy
+41,900
New +$806K ﹤0.01% 1803

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Fund Management (CFM)'s RVNC Position: Q4 2023 in Review

Capital Fund Management (CFM) sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 36,572 shares — an estimated $300K sold.

Capital Fund Management (CFM) first reported a position in RVNC in Q3 2020 and held it in 4 quarters. The position peaked at $739K in Q2 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

  • Capital Fund Management (CFM) reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 36,572 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $300K.
  • Capital Fund Management (CFM) first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 4 quarters.
  • Capital Fund Management (CFM)'s Revance Therapeutics, Inc. position peaked at $739K in Q2 2023.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2023, filed 14 Feb 2024.